Table 4 Comparisons between patients with and without ICU-acquired severe bleeding (n = 279, after excluding 17 patients with bleeding on admission)
Variable | ICU-acquired severe bleeding n = 40 patients | No ICU-acquired severe bleeding n = 239 patients | p |
|---|---|---|---|
Age | 66.5 (57.2–73) | 62 (54–69) | 0.61 |
Male gender (%) | 27 (67.5 %) | 156 (65.3 %) | 0.86 |
Underlying malignancy | 1 | ||
Hematologic malignancy | 33 (82.5 %) | 196 (82 %) | |
Solid tumor | 7 (17.5 %) | 43 (18 %) | |
Bone marrow transplantation | 5 (12.5 %) | 34 (14.2 %) | 0.87 |
Reasons for ICU admission | |||
Sepsis | 15 (37.5 %) | 124 (51.9 %) | 0.12 |
Others | 25 (62.5 %) | 115 (48.1 %) | 0.12 |
Anticoagulant and/or antiplatelet treatment | 8 (20 %) | 57 (23.8 %) | 0.69 |
Admission severity scores | |||
SAPS II (points) | 69 (34.2–80) | 51 (37–57) | 0.57 |
SOFA (points) | 8 (6–11) | 7 (5–10.7) | 0.32 |
Modified SOFA (points) | 7 (3–8) | 4 (1–7) | 0.31 |
Admission biological values | |||
Platelet count (×109/L) | 50 (26–84) | 26 (13–53) | <0.001 |
Leukopenia | 31 (77.5 %) | 133 (55.6 %) | 0.009 |
Bilirubin (μmol/L) | 21 (11–77.7) | 19 (11–40.7) | 0.36 |
Serum urea (mmol/L) | 10.9 (7.4–16.5) | 9.7 (6.8–18.6) | 0.20 |
Prothrombin time (%) | 62 (44–75) | 65 (50.2–77) | 0.41 |
Organ failures during ICU stay | |||
Nadir platelet count (×109/L)a | 15 (7–27) | 10 (6–19) | 0.014 |
Organ failure supports | |||
Renal replacement therapy | 17 (42.5 %) | 100 (42 %) | 1 |
Non-invasive ventilation | 15 (37.5 %) | 102 (42.7 %) | 0.60 |
Invasive ventilation | 28 (70 %) | 139 (58.2 %) | 0.16 |
Vasopressors | 30 (75 %) | 152 (63.6 %) | 0.21 |
In-ICU mortality | 20 (50 %) | 86 (36 %) | 0.11 |